During the last few years, concern has risen about a potential diabetes mellitus DM)-
inducing effect of some atypical antipsychotics, especially clozapine and olanzapine …

As a class, the atypical antipsychotics are the first line treatment choice for the
psychopharmacologic management of psychotic disorders. Emerging evidence currently …

As an example of iatrogenic diabetes, we discuss the problem of diabetes mellitus in
patients receiving atypical antipsychotics. The risk of diabetes mellitus appears to be …

Recently, there has been increased concern about the occurrence of diabetes associated
with the use of atypical antipsychotic (AAP) drugs. The relationship between diabetes …

Recently, increasing attention has been drawn to the potential diabetogenic effect of novel
antipsychotics. Until now, large prospective studies examining the relationship between …

Aims Atypical anti‐psychotic drugs (APDs) are widely used in psychotic disorders refractory
to conventional neuroleptic agents. Results Three cases of new‐onset diabetes are reported …

Atypical antipsychotics offer significant improvements over older, conventional antipsychotic
agents. However, recently the newer agents have been linked to medical morbidity including …

OBJECTIVE: The purpose of the study was to determine the proportion of patients with
schizophrenia with a stable regimen of antipsychotic monotherapy who developed diabetes …

Diabetes or hyperglycemia associated with the use of atypical anti-psychotic agents is a
subject of growing concern among health care providers and the patients who use the …

Background: The new antipsychotics induce minimal extrapyramidal side effects, probably
due to their relatively greater affinity for certain nondopaminergic receptors than their older …